JAMA Oncology
Papers 1868
1 page of 187 pages (1,868 results)
#1Joseph A. Sparano (Albert Einstein College of Medicine)H-Index: 58
#2Robert Gray (Harvard University)H-Index: 54
Last.Henry L. GomezH-Index: 39
view all 10 authors...
Importance A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. Objective To describe clinical outcomes for women with a high RS who received adjuvant chemotherapy plus endocrine therapy in the TAILORx trial, a population expected to have a high distant recurrence rate with endocrine therapy alone. Design, Setting, and Participants In this secondary an...
#1George W. Sledge (Stanford University)H-Index: 69
#2Masakazu Toi (Kyoto University)H-Index: 63
Last.Peter A. Kaufman (UVM: University of Vermont)
view all 10 authors...
Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not yet been demonstrated. Objective To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on OS at the prespecified interim of MONARCH 2 (338 events) in patients wi...
#1Amylou C. Dueck (Mayo Clinic)H-Index: 42
#2Howard I. Scher (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 121
Last.Ethan Basch (UNC: University of North Carolina at Chapel Hill)H-Index: 52
view all 9 authors...
Importance Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to implement in trials the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which was developed to allow patients to self-report symptomatic AEs and improve the quality of sympt...
#1Douglas B. Johnson (VUMC: Vanderbilt University Medical Center)H-Index: 36
#2Fei Ye (VUMC: Vanderbilt University Medical Center)H-Index: 8
Last.Anna K. Dewan (VUMC: Vanderbilt University Medical Center)H-Index: 1
view all 3 authors...
#1Ananta Subedi (NIH: National Institutes of Health)
#2Julius Strauss (NIH: National Institutes of Health)H-Index: 5
Last.Sarthak Gupta (NIH: National Institutes of Health)H-Index: 7
view all 3 authors...
#1Michael J. Raphael (Queen's University)
#2Andrew G. Robinson (Queen's University)H-Index: 9
Last.Michael Brundage (Queen's University)H-Index: 46
view all 7 authors...
Importance It is unclear whether patients with advanced cancer value surrogate end points, particularly progression-free survival (PFS). Despite this uncertainty, surrogate end points form the basis of regulatory approval for the majority of new cancer treatments. Objective To summarize and qualitatively assess studies evaluating whether patients with advanced cancer understand and value PFS. Evidence Review MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the Cochrane Central Regis...
#1Joseph PidalaH-Index: 34
#2Michael MartensH-Index: 4
Last.Brent R. Logan (MCW: Medical College of Wisconsin)H-Index: 47
view all 9 authors...
Importance Immune suppression discontinuation is routinely attempted after allogeneic hematopoietic cell transplantation (HCT) and under current practices may lead to graft-vs-host disease (GVHD)–associated morbidity and death. However, the likelihood and predictive factors associated with successful immune suppression discontinuation after HCT are poorly understood. Objectives To examine factors associated with successful immune suppression discontinuation and risk for immune suppression discon...